CN104547270B - It is a kind of to raise negative and positive, the drug of QI invigorating and blood or health-care food composition and its preparation method and application - Google Patents
It is a kind of to raise negative and positive, the drug of QI invigorating and blood or health-care food composition and its preparation method and application Download PDFInfo
- Publication number
- CN104547270B CN104547270B CN201510048005.6A CN201510048005A CN104547270B CN 104547270 B CN104547270 B CN 104547270B CN 201510048005 A CN201510048005 A CN 201510048005A CN 104547270 B CN104547270 B CN 104547270B
- Authority
- CN
- China
- Prior art keywords
- group
- blood
- test
- composition
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 65
- 229940079593 drug Drugs 0.000 title claims abstract description 63
- 239000008280 blood Substances 0.000 title claims abstract description 46
- 210000004369 blood Anatomy 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 235000013305 food Nutrition 0.000 title claims abstract description 7
- 230000036039 immunity Effects 0.000 claims abstract description 21
- 235000013402 health food Nutrition 0.000 claims abstract description 19
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 11
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 9
- 238000007254 oxidation reaction Methods 0.000 claims description 9
- 230000003647 oxidation Effects 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 4
- 229940100688 oral solution Drugs 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000011805 ball Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 239000003963 antioxidant agent Substances 0.000 abstract description 16
- 230000003078 antioxidant effect Effects 0.000 abstract description 16
- 235000006708 antioxidants Nutrition 0.000 abstract description 11
- 238000012423 maintenance Methods 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 96
- 239000002245 particle Substances 0.000 description 68
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 64
- 235000013923 monosodium glutamate Nutrition 0.000 description 64
- 239000004223 monosodium glutamate Substances 0.000 description 64
- 230000006870 function Effects 0.000 description 44
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 25
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 22
- 241000282414 Homo sapiens Species 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 21
- 238000007689 inspection Methods 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 18
- 230000009182 swimming Effects 0.000 description 18
- 238000009826 distribution Methods 0.000 description 17
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 14
- 102100026189 Beta-galactosidase Human genes 0.000 description 13
- 108010059881 Lactase Proteins 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 108010005774 beta-Galactosidase Proteins 0.000 description 13
- 229940116108 lactase Drugs 0.000 description 13
- 229920002527 Glycogen Polymers 0.000 description 12
- 238000013461 design Methods 0.000 description 12
- 229940096919 glycogen Drugs 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 11
- 229960003180 glutathione Drugs 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000003064 anti-oxidating effect Effects 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000002440 hepatic effect Effects 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 230000005180 public health Effects 0.000 description 8
- 238000010998 test method Methods 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 7
- 206010018910 Haemolysis Diseases 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000002949 hemolytic effect Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108010024636 Glutathione Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 5
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000011981 development test Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- -1 oxygen radical Chemical class 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 229940109850 royal jelly Drugs 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 230000007118 DNA alkylation Effects 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000270708 Testudinidae Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241001482311 Trionychidae Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- GZCGUPFRVQAUEE-KCDKBNATSA-N aldehydo-D-galactose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Abstract
The present invention provides the drugs or health-care food composition of a kind of maintenance negative and positive, QI invigorating and blood, it is the preparation that the raw material matched by following weight is prepared：1-3 parts of American Ginseng, 3-15 parts of matrimony vine, 3-15 parts of Radix Salviae Miltiorrhizae, 3-15 parts of Herba Epimedii.The present invention also provides the preparation method of the composition and purposes.The present composition has effects that alleviate physical fatigue, anti-oxidant and strengthen immunity, and clear efficacy, and composition by the raw material of medicine-food two-purpose or can be used for the article of health food and form, and safety is used for a long time, without side-effects.
Description
Technical field
The present invention relates to the drug of a kind of maintenance negative and positive, QI invigorating and blood or health-care food composition and preparation method thereof and use
On the way.
Background technology
Due to the various pressure of present society, people is usually made to feel that frequent alopecia, decrease of memory, attention do not collect
In, mood it is passionnate, it is physical worse and worse, often headache, tinnitus, dizzy etc., this illustrates that body has probably been in
Fatigue state.Fatigue is a kind of subjective uncomfortable feeling, but objectively under equal conditions can lose what its completion was engaged in originally
Normal activity or ability to work.Being used for anti-fatigue health-product containing primary raw material currently on the market has ginseng, American Ginseng, taurine.Its
Middle American Ginseng is mended without dry, and the young equal edible of child old man has unique advantage.
Deferring senility is health ministry in June, 1996 publication " function of health food assessment process and method " rule
One of first fixed 12 kinds of healthcare functions.State Food and Drug Administration in 2003 is to original 22 kinds of health foods
Function is adjusted to 27 kinds, and wherein deferring senility is adjusted to anti-oxidation function.The anti-oxidation active substance packet investigated thoroughly at present
Free radical scavenger and immune sharp agent etc. are included, free radical scavenger includes two class of antioxidant and antioxidase.The Ministry of Public Health has criticized
The accurate substance with deferring senility has：Metallothionein, ginseng, superoxide dismutase, ganoderma lucidum, pearl, matrimony vine, bee
Royal jelly, cordyceps sinensis, tortoise, soft-shelled turtle, sheep placenta, ant, ginkgo leaf, seal oil, chitosan, pilose antler, black fungus, Poria cocos, Herba Cistanches, mountain
Medicine, mulberries, white fungus, silkworm chrysalis, Radix Astragali, grape seed extract, vitamin E, soybean lecithin, gamma-Linolenic acid, Semen sesami nigrum and isomery
Change lactose.
Anti-oxidant refers to the abbreviation of resisting oxidation free radical, English Anti-Oxidant.Human body with extraneous because persistently connect
It touches, including the factors such as breathing (oxidation reaction), outside contamination, radioactive ray irradiation constantly generate free radicals in body.Section
It learns studies have shown that cancer, aging or Other diseases are mostly relevant with the generation of excessive free radicals.Study it is anti-oxidant can be effective
Its caused harm is overcome, so anti-oxidant be classified as one of main R＆D direction and city by health products, Management of Cosmetics Enterprises
One of most important functional demand in field.Immunity is the defense mechanism of human body itself, is human bioequivalence and the external intrusion of elimination
Any foreign matter (virus, bacterium etc.).It handles aging, damage, death, the own cells of denaturation and identification and processing is prominent in vivo
Become the ability of cell and virus infected cell.
The health products for being used to increase immunity currently on the market mainly have two major classes.The first kind is containing needed for immune system
The category of a variety of critical nutrients.The characteristics of this kind of product, is suitble to more comprising the various nutrients needed for human immune system
The immunocompromised person that kind nutrient lacks.Since the crowd of most immune force differences has the performance of various nutrients shortage, because
This this kind of product occupies mainstream on the market.This class product is mainly with propolis, royal jelly, spirulina, pollen, ginseng, the West
Ginseng, ganoderma lucidum, lucidum spore powder, colostrum class are representative.Second class is containing certain specific nutrition element needed for immune system
Category, such as protein powder, vitamin, probiotics, Co-Q10, garlic P.E.Commercially available antifatigue, anti-aging increases
The health products kind of immunity is numerous, and effect is different, and different effects is played according to respectively different raw material proportionings.
Invention content
The technical solution of the present invention is to provide a kind of maintenance negative and positive, QI invigorating and blood drug or health-care food composition and
Preparation method and use.
The present invention provides the drugs or health-care food composition of a kind of maintenance negative and positive, QI invigorating and blood, it is by following heavy
The preparation that the raw material of amount proportioning is prepared：
1-3 parts of American Ginseng, 3-15 parts of matrimony vine, 3-15 parts of Radix Salviae Miltiorrhizae, 3-15 parts of Herba Epimedii.
It is further preferred that it is the preparation that the raw material matched by following weight is prepared：
1 part of American Ginseng, 5 parts of matrimony vine, 5 parts of Radix Salviae Miltiorrhizae, 5 parts of Herba Epimedii.
The present composition be by American Ginseng, matrimony vine, Radix Salviae Miltiorrhizae, Herba Epimedii primary medicinal powder, water or extractive with organic solvent
For active constituent, pharmaceutically acceptable auxiliary material is added or complementary ingredient is prepared into pharmaceutically common preparation.
Wherein, the preparation is tablet, granule, capsule, pill, oral solution, vina.
The present invention also provides a kind of methods preparing the composition, it includes the following steps：
A, the raw material of each weight proportion is weighed；
B, extraction is added water to cook, is filtered, filtrate concentration is added pharmaceutically acceptable auxiliary material or complementary ingredient is prepared into
Pharmaceutically common preparation.
The present invention also provides purposes of the composition in preparing the drug or health food of alleviating physical fatigue.
The present invention also provides purposes of the composition in preparing oxidation resistant drug or health food.
The present invention also provides purposes of the composition in the drug or health food for preparing strengthen immunity.
Traditional Chinese medical theory thinks that negative and positive of qi and blood is body material's composition and the four big fundamentals that function generates, high and level tone sun
Secret, gentle qi and blood is health stable state, once yin and yang imbalance or disorder of qi and blood, human body will be in sub-health state and even send out
Exhibition is disease.Therefore, when body is in inferior health or morbid state, recuperating qi-blood negative and positive is needed, subtract it actually, it is empty then beneficial
It, adjustment negative and positive of qi and blood is then expected the state of getting well to relative balance state.The present composition is by American Ginseng, Radix Salviae Miltiorrhizae, Chinese holly
Matrimony vine, Herba Epimedii four traditional Chinese medicine eat article composition that is dual-purpose or can be used for health food, are respectively provided with QI invigorating and blood, enriching yin, establishing-Yang
Effect, combines and preparation is made, and just possesses the allomeric function for raising negative and positive, QI invigorating and blood, can be in and lose in negative and positive of qi and blood
When weighing apparatus state, plays adjustment negative and positive of qi and blood and restore to definite effect of equilibrium state.This adjusts four human body bases of negative and positive of qi and blood
Essentiality is played alleviate physical fatigue, anti-oxidant and strengthen immunity effect mechanism altogether.
The present composition has effects that alleviation physical fatigue, anti-oxidant and strengthen immunity, and clear efficacy, and
By medicine-food two-purpose raw material or can be used for the article of health food and form, safety is used for a long time, it is without side-effects.
Specific implementation mode
1 granule of the present invention of embodiment is (hereinafter referred to as：Four monosodium glutamate particles) preparation
Raw material prescription：American Ginseng 100Kg matrimony vine 500g Radix Salviae Miltiorrhizae 500g Herba Epimedii 500g
Preparation method：
Four traditional Chinese medicine material is taken, (American Ginseng shave, Radix Salviae Miltiorrhizae crushing are pre-processed to medicinal material according to pharmaceutical decocting piece concocted specification
At coarse granule etc.), decoction is secondary, every time 10 times of water, 1.5 hours every time, merging filtrate, and filtration stands 24 hours, discards precipitation
It is condensed into cream after object, the auxiliary materials such as appropriate dextrin, sucrose are added, particle is made, whole grain dispenses up to 600g granules.
Effect：Raise negative and positive, QI invigorating and blood.For alleviating physical fatigue, anti-oxidant and strengthen immunity.
【Specification】6g/ bags.(16g crude drugs/6g granules/bag)
【Usage and dosage】It is oral, one time 1-2 bags, 1 times a day.
The preparation of 2 Tablets of embodiment
Take raw material prescription：American Ginseng 100g, matrimony vine 300g, Radix Salviae Miltiorrhizae 300g, Herba Epimedii 300g；It crushes, sieving, powder is direct
Tabletting is to get tablet.
The preparation of 3 oral solution of the present invention of embodiment
Take raw material prescription：American Ginseng 300g, matrimony vine 300g, Radix Salviae Miltiorrhizae 1500g, Herba Epimedii 1500g, add water to cook, and concentrate, system
For at oral solution.
Beneficial effects of the present invention are proved below by way of specific efficacy test.
1 health food function of physical fatigue alleviation of the present invention of test example is evaluated
One, function of physical fatigue alleviation evaluation-serum urea nitrogen determination experiment
1, test method
1.1 grouping
The qualified all-male mouse 40,18.0~21.9g of weight of quarantine is taken, weight is divided into 4 groups according to the random district's groups method of dividision into groups,
That is control group, four monosodium glutamate particles (granule that i.e. prepared by embodiment 1) high, medium and low dosage group, every group of 10 animals.Grouping with
Machine number, group are corresponding with test number to be shown in Table 1.
The experiment grouping of table 1 random number, group table corresponding with test number
1.2 dose designs and foundation
Dose design：
(1) test sample group：According to the Ministry of Public Health《Health food is examined and assessment technique specification》Alleviate body in (version in 2003)
The power fatigue function method of inspection, " experiment sets three dosage groups and negative control group, with 10 times of human body recommended amounts for therein one
A dosage group separately sets two dosage groups ", 5,10,20 times of tested material day for human beings recommended amounts are pressed in this experiment, if four monosodium glutamate particles
Basic, normal, high dosage is followed successively by 1.34g/kg, 2.67g/kg and 5.34g/kg, is specifically shown in Table 2.
(2) negative control group：Give test sample group isometric purified water.
1.3 medication
(1) administration route：Select clinical application approach --- gastric infusion.
(2) administered volume：Administered volume selects 10ml/kg.
(3) administration frequency and period：1 time a day, continuous 30d.Dosage regimen is shown in Table 2.
2 four monosodium glutamate particle function of physical fatigue alleviation evaluation of table-serum urea nitrogen determination tests dosage regimen
1.4 modeling methods and Testing index
(1) weight inspection：Administration phase is weighed weekly 1 time, and calculates animal dosage according to changes of weight.
(2) modeling method：After last is to mouse tested material 30min, the not swimming with a load attached to the body in the water that temperature is 30 ± 0.5 DEG C
90min。
(3) serum urea measures：It plucks eyeball blood sampling 0.5ml after movement after rest 60min immediately, is centrifuged with 2000r/min
15min takes serum automatic clinical chemistry analyzer to measure serum urea values of nitrogen might.
1.5 data statistics processing
Urea data are measurement data, and average, standard deviation are calculated using Excel softwares, judge whether data are in normal state
Distribution, normal distribution then use F in excel to examine progress homogeneity test of variance, t inspections are then selected to be counted；To it is non-just
State or the data of heterogeneity of variance carry out variable conversion appropriate, after meeting normal state or homogeneity of variance requirement, with transformed number
According to being counted；If being still not up to normal state or the neat purpose of variance after variable conversion, uses rank sum test instead and counted.
1.6 result judgement
Test sample group serum urea is less than control group, and difference is significant, can determine that the given the test agent has and alleviates
The effect of physical fatigue.
2, result and analysis
3 four monosodium glutamate particle function of physical fatigue alleviation evaluation of table-serum urea nitrogen determination test result
Note：Each administration group * p compared with the control group<0.05**P<0.01
The display of table 3, compared with the control group, four monosodium glutamate particle high dose groups (5.34g crude drugs/kg) and middle dose group (2.67g
Crude drug/kg) mice serum urea nitrogen content significantly or apparently be less than control group (P<0.01 or P<0.05), low dose of four monosodium glutamate particle
Amount group (1.34g crude drugs/kg) mice serum urea nitrogen content difference unobvious (P ＞ 0.05).It is urinated according to test sample group serum
Plain nitrogen is less than control group, and difference is significant, can determine that the given the test agent has the function of alleviating physical fatigue, the results showed that
Four monosodium glutamate particles have the function of alleviating physical fatigue.
Brief summary：Four monosodium glutamate particles have certain alleviation to make physical fatigue in 2.67-5.34g crude drugs/kg dosage ranges
With.
Two, four monosodium glutamate particle function of physical fatigue alleviation evaluations-mice burden swimming test
1, test method
1.1 test principle
The raising of tolerance of exercise is that anti-fatigue ability is reinforced most directly showing, and the length of swimming time can react dynamic
The degree of object sports fatigue.
1.2 grouping
Pair the qualified all-male mouse 40,18.6~21.9g of weight of quarantine is taken, is divided into 4 groups according to the random district's groups method of dividision into groups, i.e.,
According to group, the four high, medium and low dosage groups of monosodium glutamate particle, every group of 10 animals.Grouping random number, group is corresponding with test number is shown in Table
4。
The experiment grouping of table 4 random number, group table corresponding with test number
1.3 dose designs and foundation
Dose design：
(1) test sample group：According to the Ministry of Public Health《Health food is examined and assessment technique specification》Alleviate body in (version in 2003)
The power fatigue function method of inspection, " experiment sets three dosage groups and negative control group, with 10 times of human body recommended amounts for therein one
A dosage group separately sets two dosage groups ", 5,10,20 times of tested material day for human beings recommended amounts are pressed in this experiment, if four monosodium glutamate particles
Basic, normal, high dosage is followed successively by 1.34g crude drugs/kg, 2.67g crude drug/kg and 5.34g crude drugs/kg, is specifically shown in Table 5.
(2) control group：Give test sample group isometric purified water.
1.4 medication
(1) administration route：Select clinical application approach --- gastric infusion.
(2) administered volume：Administered volume selects 10ml/kg.
(3) administration frequency and period：1 time a day, continuous 30d.Dosage regimen is shown in Table 5.
5 four monosodium glutamate particle function of physical fatigue alleviation evaluation of table-mice burden swimming test dosage regimen
1.5 modeling methods and Testing index
(1) modeling method：After last gives mouse tested material 30min, it is placed in swimming trunk went swimming, the depth of water about 30cm, water
Warm (25 ± 0.5) DEG C, the sheet lead of 4.5% weight of mouse tail root load, per 8, pond mouse, parallel determination each group mouse is negative
Weight swimming time.
(2) walking weight load：Record mouse from swim to death time.
(3) weight inspection：Administration phase weighs weekly 1 time and calculates animal dosage according to changes of weight.
1.6 data statistics processing
Swimming time is measurement data, and average, standard deviation are calculated using Excel softwares, judges whether data are in normal state
Distribution, normal distribution then use F in excel to examine progress homogeneity test of variance, t inspections are then selected to be counted；To it is non-just
State or the data of heterogeneity of variance carry out variable conversion appropriate, after meeting normal state or homogeneity of variance requirement, with transformed number
According to being counted；If being still not up to normal state or the neat purpose of variance after variable conversion, uses rank sum test instead and counted.
1.7 result judgement
Test sample group walking weight load is considerably longer than control group, and difference is significant, can determine that the given the test agent
Have the function of alleviating physical fatigue.
2, result and analysis
6 four 30 days mice burden swimming test results of monosodium glutamate particle successive administration of table
Note：Each administration group * p compared with the control group<0.05***p<0.001
Table 6 is shown, and is compared, four monosodium glutamate particle high dose groups (5.34g crude drugs/kg) and middle dose group (2.67g lifes
Medicine/kg) there is the difference (P of pole conspicuousness in the mice burden swimming time<0.0001), (1.34g gives birth to four monosodium glutamate particle low dose groups
Medicine/kg) there is notable difference (P in the mice burden swimming time<0.05).It is considerably longer than pair according to test sample group walking weight load
According to group, and difference is significant, can determine that the given the test agent has the function of alleviating physical fatigue, the results showed that four monosodium glutamate particles
Have the function of centainly alleviating physical fatigue.
Brief summary：Four monosodium glutamate particles have certain alleviation to make physical fatigue in 1.34-5.34g crude drugs/kg dosage ranges
With.
Three, four monosodium glutamate particle function of physical fatigue alleviation evaluations-hepatic glycogen measures experiment
1, test method
1.1 grouping
Pair the qualified all-male mouse 40,19.0~21.9g of weight of quarantine is taken, is divided into 4 groups according to the random district's groups method of dividision into groups, i.e.,
According to group, the four high, medium and low dosage groups of monosodium glutamate particle, every group of 10 animals.Grouping random number, group is corresponding with test number is shown in Table
7。
The experiment grouping of table 7 random number, group table corresponding with test number
1.2 dose designs and foundation
Dose design：(1) test sample group：According to the Ministry of Public Health《Health food is examined and assessment technique specification》(version in 2003)
The middle function of physical fatigue alleviation method of inspection, " experiment sets three dosage groups and negative control group, and 10 times with human body recommended amounts are
One of dosage group separately sets two dosage groups ", 5,10,20 times of tested material day for human beings recommended amounts are pressed in this experiment, if four tastes
The basic, normal, high dosage of crude granule is followed successively by 1.34g/kg, 2.67g/kg and 5.34g/kg, is specifically shown in Table 8.
(2) negative control group：Give test sample group isometric purified water.
1.3 medication
(1) administration route：Select clinical application approach --- gastric infusion.
(2) administered volume：Administered volume selects 10ml/kg.
(3) administration frequency and period：1 time a day, continuous 30d.Dosage regimen is shown in Table 8.
8 four monosodium glutamate particle function of physical fatigue alleviation evaluation of table-hepatic glycogen measures experiment dosage regimen
1.4 modeling methods and Testing index
(1) weight inspection：Administration phase is weighed weekly 1 time, and calculates animal dosage according to changes of weight.
(2) hepatic glycogen measures：Last weighs mouse liver 100mg to anesthesia is put to death immediately after mouse tested material 30min,
Hepatic glycogen measurement is carried out by hepatic glycogen assay kit specification.
1.5 data statistics processing
Whether hepatic glycogen data are measurement data, and average, standard deviation are calculated using Excel softwares, judge data in just
State is distributed, and normal distribution then uses F in excel to examine progress homogeneity test of variance, and t inspections is then selected to be counted；To non-
Normal state or the data of heterogeneity of variance carry out variable conversion appropriate, and after meeting normal state or homogeneity of variance requirement, use is transformed
Data are counted；If being still not up to normal state or the neat purpose of variance after variable conversion, uses rank sum test instead and counted.
1.6 result judgement
Test sample group hepatic glycogen content is apparently higher than control group, and difference is significant, can determine that the given the test agent has
Play the role of alleviating physical fatigue.
2, result and analysis
9 four monosodium glutamate particle function of physical fatigue alleviation evaluation of table-hepatic glycogen measures test result
Note：Each administration group * * * p compared with the control group<0.001
Table 9 is shown, and is compared, four monosodium glutamate particle high dose groups (5.34g crude drugs/kg) and middle dose group (2.67g lifes
Medicine/kg) mouse hepatic glycogen content pole is significantly higher than control group (P<0.001), four monosodium glutamate particle low dose groups (1.34g crude drugs/
Kg) mouse hepatic glycogen content difference unobvious (P ＞ 0.05).Test sample group hepatic glycogen content is apparently higher than control group, and poor
It is different significant, it can determine that the given the test agent has the function of alleviating physical fatigue, show that four monosodium glutamate particles have certain alleviate
The effect of physical fatigue.
Brief summary：Four monosodium glutamate particles have certain alleviation to make physical fatigue in 2.67-5.34g crude drugs/kg dosage ranges
With.
Four, four monosodium glutamate particle function of physical fatigue alleviation evaluations-blood lactase acid measures experiment
1, test method
1.1 grouping
Pair the qualified all-male mouse 40,19.3~21.8g of weight of quarantine is taken, is divided into 4 groups according to the random district's groups method of dividision into groups, i.e.,
According to group, the four high, medium and low dosage groups of monosodium glutamate particle, every group of 10 animals.Grouping random number, group is corresponding with test number is shown in Table
10。
The experiment grouping of table 10 random number, group table corresponding with test number
1.2 dose designs and foundation
Dose design：(1) test sample group：According to the Ministry of Public Health《Health food is examined and assessment technique specification》(version in 2003)
The middle function of physical fatigue alleviation method of inspection, " experiment sets three dosage groups and negative control group, and 10 times with human body recommended amounts are
One of dosage group separately sets two dosage groups ", 5,10,20 times of tested material day for human beings recommended amounts are pressed in this experiment, if four tastes
The basic, normal, high dosage of crude granule is followed successively by 1.34g crude drugs/kg, 2.67g crude drug/kg and 5.34g crude drugs/kg, is specifically shown in Table 11.
(2) negative control group：Give test sample group isometric purified water.
1.3 medication
(1) administration route：Select clinical application approach --- gastric infusion.
(2) administered volume：Administered volume selects 10ml/kg.
(3) administration frequency and period：1 time a day, continuous 30d.Dosage regimen is shown in Table 11.
11 4 monosodium glutamate particle function of physical fatigue alleviation evaluation of table-hepatic glycogen measures experiment dosage regimen
1.4 modeling methods and Testing index
(1) weight inspection：Administration phase is weighed weekly 1 time, and calculates animal dosage according to changes of weight.
(2) blood sampling before swimming：After last is to tested material 30min, vena ophthalmica take a blood sample 20ul, it is parallel to take each group mouse complete
Blood.
(3) 0min takes a blood sample after swimming：Mouse after above-mentioned blood sampling is not born a heavy burden in 30 DEG C of ± 0.5 DEG C of water went swimmings of water temperature, often
It is put into one every 1min, is taken out immediately after the 10min that swims, dries moisture, respectively take a blood sample 20ul.
(4) rest 20min blood samplings after swimming：Take a blood sample 20ul again after quiet 20min.
(5) blood lactase acid measures：After taking blood, blood lactase acid measurement is carried out by lactic acid (LD) assay kit specification.
(6) blood lactase acid area under the curve is calculated
Blood lactase acid area under the curve=5 × (before swimming after blood lactase acid value+3 × swimming after 0min blood lactase acids value+2 × swimming
Rest 20min blood lactase acids value).
1.5 data statistics processing
Whether blood lactase acid data are measurement data, and average, standard deviation are calculated using Excel softwares, judge data in just
State is distributed, and normal distribution then uses F in excel to examine progress homogeneity test of variance, and t inspections is then selected to be counted；To non-
Normal state or the data of heterogeneity of variance carry out variable conversion appropriate, and after meeting normal state or homogeneity of variance requirement, use is transformed
Data are counted；If being still not up to normal state or the neat purpose of variance after variable conversion, uses rank sum test instead and counted.
1.6 result judgement
Judged with three time point blood lactase acid area under the curve.The area of any test group is less than control group, and difference
It is significant, it can determine that the given the test agent has the function of alleviating physical fatigue.
2, result and analysis
12 4 monosodium glutamate particle function of physical fatigue alleviation evaluation of table-blood lactase acid measures test result
Note：Each administration group * * P compared with the control group<0.01 ***P<0.001
Table 12 is shown, and is compared, four monosodium glutamate particle high dose groups (5.34g crude drugs/kg) and middle dose group (2.67g
Crude drug/kg) mouse blood lactase acid area under the curve extremely significantly or substantially less than control group (P<0.001 or P<0.01), four monosodium glutamate
Grain low dose group (1.34g crude drugs/kg) mouse Serum lactic acid content difference unobvious (P ＞ 0.05), but have reduction trend, show four
Monosodium glutamate particle can reduce the blood lactase acid area under the curve after mouse movement.According to result judgement standard " with three time point blood breasts
Sour area under the curve judges that the area of any test group is less than control group, and difference is significant, can determine that the given the test agent
Have the function of alleviating physical fatigue ", therefore judge that four monosodium glutamate particles have the function of centainly alleviating physical fatigue.
Brief summary：Four monosodium glutamate particles have certain alleviation to make physical fatigue in 2.67-5.34g crude drugs/kg dosage ranges
With.
2 four monosodium glutamate particle anti-oxidation efficacy development test of test example
1, test method
1.1 modeling
1. principle：The supply of D- galactolipins is excessive, extraordinary generation active oxygen, has broken the active oxygen production for being controlled by hereditary pattern
The raw equilibrium state with elimination causes peroxidating effect.
2. modeling method：The qualified mouse 50 of quarantine is taken, first chooses female, male each 5 animals as Normal group, remaining
Modeling, one time a day, continuous modeling 42 days is injected intraperitoneally with D- galactolipin 600mg/10ml/kg BW in 40 animals.
1.2 grouping
0.5h after last modeling, immediately eye socket take blood>1ml, 4000r/min centrifuge 15min, detach serum, are measured by MDA
Kit specification operating method is at 532nm wavelength, 1cm optical paths, and distilled water zeroing measures each pipe OD values, then as the following formula
Calculate MDA contents in serum：
It is grouped by MDA levels, is randomly divided into 4 groups, i.e. D- galactolipins model control group, the four high, medium and low dosage of monosodium glutamate particle
Group, every group of 10 animals.Grouping random number, group is corresponding with test number is shown in Table 13.
13 random number of table, group table corresponding with test number
1.3 administration
Administration route：Select clinical application approach --- gastric infusion.
Dosage designs：1. test sample group：According to the Ministry of Public Health《Health food is examined and assessment technique specification》(2003
Version) in the anti-oxidation function method of inspection separately set two dosage groups with 5 times of human body recommended amounts for one of dosage group, it is high
Dosage is usually no more than 30 times, and 5,10,20 times of tested material day for human beings recommended amounts are pressed in this experiment, if basic, normal, high dose of four taste particle
Amount is followed successively by 1.34g/kg, 2.67g/kg and 5.34g/kg, is specifically shown in Table 14.
2. Normal group：Give isometric purified water.
3. D- galactolipin model control groups：Give isometric purified water.
In addition to Normal group, D- galactolipins model control group and the high, medium and low each dosage group of four monosodium glutamate particles are to tested
While sample, continues intraperitoneal injection and give 600mg/10ml/kg BW D- galactose solutions.
Administered volume：Administered volume selects 10ml/kg.
Administration frequency and period：1 time a day, continuous 30d.Dosage regimen is shown in Table 14.
14 4 monosodium glutamate particle anti-oxidation efficacy development test dosage regimen of table
1.4 Testing index
Administration phase is weighed weekly 1 time, and calculates animal dosage according to changes of weight.
0.5h after last dose, after 10% chloraldurate solution 0.1ml anesthesia of mouse peritoneal injection, at cervical dislocation
Extremely, it is rapidly separated mouse liver tissue, is frozen in -80 DEG C of refrigerators.
Detection：0.4g hepatic tissues are weighed, shreds and is placed in glass homogenizer, adds 9 times of pre- cold salines of volume, is made
The liver tissue homogenate of 10% (W/V), 3000r/min centrifuge 10min, and supernatant is taken to measure liver cell egg by kit operating method
Degree, reductive glutathione (GSH), lipid oxidation products malonaldehyde (MDA) and antioxidant enzyme superoxide is carbonylated in white matter
Mutase (SOD) activity.
1.5 data statistics processing
Anti-oxidation function checks that data are measurement data, calculates average, standard deviation using Excel softwares, judges data
Whether it is in normal distribution, normal distribution then uses F in excel to examine progress homogeneity test of variance, t inspections is then selected to unite
Meter；If being in Non-Gaussian Distribution, non-parametric test is carried out.
1.6 result judgement
Protein carbonylation degree, antioxidant enzyme superoxide mutase (SOD), lipid oxidation products malonaldehyde (MDA)
And arbitrary three indexs are the positive in reductive glutathione (GSH) four indices, can determine that the anti-oxidant animal of the given the test agent
Experimental result is the positive.
2, result and analysis
15 4 monosodium glutamate particle anti-oxidation efficacy development test result of table
Note：1. model control group is compared with Normal group▲▲▲p<0.001 2. each administration group * p compared with model control group
<0.05 **p<0.01***p<0.001
Table 15 shows that 1. successive administration is after 30 days, and for D- galactolipin model control groups compared with Normal group, Mouse Liver is thin
Born of the same parents' lipid oxidation products malonaldehyde (MDA) and content of protein carbonyl group extremely significantly increase (P<0.001), reductive glutathione
(GSH) content and antioxidant enzyme superoxide mutase (SOD) vigor pole significantly reduce, and illustrate modeling success.2. with D- galas
Sugared model control group compares, four monosodium glutamate particle high dose groups (5.34g crude drugs/kg), middle dose group (2.67g crude drugs/kg) and low
Dosage group (1.34g crude drugs/kg) can extremely notable and highly significant reduction lipid oxidation products malonaldehyde (MDA) content and protein
Carbonyl content (P<0.001, P<0.001, P<0.01)；Four monosodium glutamate particle high dose groups (5.34g crude drugs/kg) and middle dose group
(2.67g crude drugs/kg) extremely can significantly increase reductive glutathione (GSH) content and antioxidant enzyme superoxide mutase
(SOD) vigor (P<0.001, P<0.001).Analysis reason may be significantly improved with GSH contents and SOD vigor, be greatly strengthened
The ability for removing and inhibiting oxygen radical, generation reduction and content of protein carbonyl group to make MDA reduce.Experimental result table
Bright, four monosodium glutamate particles can reduce malonaldehyde (MDA) and content of protein carbonyl group, increase reductive glutathione (GSH) content and
Antioxidant enzyme superoxide mutase (SOD) vigor, four indices are positive, and it is oxidation resistant to can determine that the given the test agent has
Effect, and the effect of antioxidant stress injury is in docs-effect positive correlation.
Brief summary：Four monosodium glutamate particles can effectively remove free radical and active oxygen in 2.67-5.34g crude drugs/kg dosage ranges,
Has certain anti-oxidation function.
3 four monosodium glutamate particle strengthen immunity function of test example
One, four monosodium glutamate particle strengthen immunity functional evaluation-blood leucocyte number measures Test Summary
1, test method
1.1 grouping
Take quarantine qualification C57BL/6J mouse 50, gynoecy, 18.0~20.7g of weight, according to the random district's groups method of dividision into groups
It is divided into 5 groups, i.e. negative control group, model control group, the four high, medium and low dosage groups of monosodium glutamate particle, every group 10, totally 5 groups, with
Machine number, group are corresponding with test number to be shown in Table 16.
16 random number of table, group table corresponding with test number
Dosage designs：1. test sample group：According to the Ministry of Public Health《Health food is examined and assessment technique specification》(2003
Version) in the anti-oxidation function method of inspection separately set two dosage groups with 5 times of human body recommended amounts for one of dosage group, it is high
Dosage is usually no more than 30 times, and 5,10,20 times of tested material day for human beings recommended amounts are pressed in this experiment, if four monosodium glutamate particles are basic, normal, high
Dosage is followed successively by 1.34g/kg, 2.67g/kg and 5.34g/kg, is specifically shown in Table 17.
2. Normal group：Give isometric purified water.
3. model control group：Give isometric purified water.
1.2 medication
(1) administration route：Select clinical application approach --- gastric infusion.
(2) administered volume：Administered volume selects 10ml/kg.
(3) administration frequency and period：1 time a day, continuous 28d.Dosage regimen is shown in Table 17.
17 4 monosodium glutamate particle strengthen immunity functional evaluation of table-blood leucocyte number measures experiment dosage regimen
1.3 modeling methods and Testing index
1. principle：It is thin that cyclophosphamide mainly non-specifically kills lymph by the synthesis of DNA alkylation destructions DNA
Born of the same parents, and can inhibit lymphocyte transformation；Cyclophosphamide is stronger than T cell to the inhibition of B cell, generally has to humoral immunity very strong
Inhibiting effect, it is weaker to the inhibiting effect of NK cells.Cyclophosphamide model is relatively suitble to antibody-producting cell detection, serum hemolysis
Element measures, total white blood cells measure.
2. modeling method：It is administered the 22nd day, for each group while continuing administration, in addition to Normal group, each group animal is equal
The cyclophosphamide modeling of 40mg/10ml/kg BW is injected intraperitoneally, one time a day, continuous modeling 2 days, the 5th day after final injection administration
It is administered and measures within the 28th day peripheral white blood cells sum.
3. Testing index
Administration phase is weighed weekly 1 time, and calculates animal dosage according to changes of weight.
After last dose, wins eyeball of mouse and take whole blood (>=0.5ml) with 1.5ml centrifuge tubes, then use pipettor
It takes 0.3ml whole bloods to be added and contains 50 μ l 2.2%EDTA-K2Anti-freezing in the polyethylene tube of anti-coagulants (60~80 DEG C of drying in advance).
Interior for 24 hours with automatic clinical chemistry analyzer detection peripheral white blood cells sum.
1.4 data statistics processing
Whether total white blood cells are measurement data, and average, standard deviation are calculated using Excel softwares, judge data in just
State is distributed, and normal distribution then uses F in excel to examine progress homogeneity test of variance, and t inspections is then selected to be counted；If being in
Non-Gaussian Distribution then carries out non-parametric test.
1.5 result judgement
The total white blood cells of test sample group are significantly higher than model control group, can determine that this experimental result positive.
2, result and analysis
18 4 monosodium glutamate particle strengthen immunity functional evaluation of table-blood leucocyte number measures test result
Note：1. model control group is compared with Normal group▲▲▲p<0.001 2. each administration group * p compared with model control group
<0.05 **p<0.01***p<0.001
Table 18 shows that 1. successive administration is after 28 days, and compared with Normal group, leukocyte count extremely significantly drops model control group
Low (P<0.001), illustrate modeling success.2. compared with model control group, four monosodium glutamate particle high dose groups (5.34g crude drugs/kg),
Middle dose group (2.67g crude drugs/kg) and low dose group (1.34g crude drugs/kg) murine interleukin number difference extremely significantly (P<
0.001), highly significant (P<And apparent (P 0.01)<0.05) it is higher than model control group.Test sample group leukocyte count is obviously high
In model control group, and difference is significant, can determine that the given the test agent has the function of enhancing Immunity regulation, and enhance
Immunologic Functions are in docs-effect positive correlation.
Brief summary：Four monosodium glutamate particles have certain tune in 1.34-5.34g crude drugs/kg dosage ranges to enhancing immune function
Section acts on.
Two, four monosodium glutamate particle strengthen immunity functional evaluation-half hemolytic value (HC50) measures experiment
1, test method
1.1 test principle
After animal is immunized with SRBC, anti-SRBC antibody (hemolysin) is generated, in complement presence, is incubated with SRBC,
Hemolytic reaction can occur, discharge hemoglobin, the content of hemolysin in animal blood serum is reflected by measuring content of hemoglobin.
1.2 Specimen origins and preparation
It takes in " four monosodium glutamate particle strengthen immunity functional evaluation-antibody-producting cell detection experiment " and is administered the 28th day normally
Control group, model control group, the four high, medium and low dosage groups of taste particle, mouse orbit take blood about 1ml in centrifuge tube, place about
1h makes serum fully be precipitated, and 2000r/min centrifuges 10min, collects serum.
1.3 detection method
1. setting sample well and blank control wells.
2. sample well：10 μ l of serum are taken, with 1ml 1：5 diluted SA buffer solutions dilute, and the blood after dilution is added in every hole
Clear 100 μ l.
3. blank control wells：100 μ l 1 are added per hole：5 diluted SA buffer solutions.
10% (v/v) SRBC, 50 μ l are sequentially added, 100 μ l of complement (press 1 with SA solution or PBS solution：8 dilutions), it sets
30min is kept the temperature in 37 DEG C of waters bath with thermostatic control, 1500r/min centrifuges 10min.
4. then sample well and blank control wells respectively take 50 μ l of supernatant to be added in another 96 well culture plate, Dou Shi is added to try
150 μ l of agent.
5. setting half hemolysis hole simultaneously, 10% (v/v) SRBC, 12.5 μ l are added, then add Dou Shi reagents to 200 μ l.
6. being mixed well with oscillator, after placing 10min, each hole optical density is measured with full-automatic microplate reader at 540nm
Value.
1.4 data statistics processing
Half hemolytic value (HC50), which measures, checks that data are measurement data, and average, standard are calculated using Excel softwares
Difference judges whether data are in normal distribution, and normal distribution then uses F in excel to examine progress homogeneity test of variance, then selects
T inspections are counted；If being in Non-Gaussian Distribution, non-parametric test is carried out.
The amount of hemolysin is with half hemolytic value (HC50) indicate, it is calculated according to the following formula：
1.5 result judgement
The HC of test sample group50It is significantly higher than the HC of control group50, can determine that this test result positive.
2, result and analysis
19 4 monosodium glutamate particle strengthen immunity functional evaluation of table-half hemolytic value (HC50) measure test result
Note：1. model control group is compared with Normal group▲▲▲p<0.001 2. each administration group and model control group ratio
Compared with * * * p<0.001
Table 19 shows that compared with Normal group, 1. model control group half hemolytic value pole is substantially less than Normal group
(P<0.001), illustrate modeling success.2. compared with model control group, four monosodium glutamate particle high dose groups (5.34g crude drugs/kg), in
Dosage group (2.67g crude drugs/kg) and low dose group (1.34g crude drugs/kg), can pole significantly improve mouse half hemolytic value P<
0.001).3. according to the result judgement standard " HC of test sample group50It is significantly higher than the HC of control group50, can determine that this tests
As a result positive ", therefore judge that four monosodium glutamate particles have the function of strengthen immunity function.
Brief summary：Four monosodium glutamate particles in 1.34~5.34g crude drugs/kg dosage ranges there is enhancing to exempt from function.
Three, four monosodium glutamate particle strengthen immunity functional evaluation-antibody-producting cell detection experiment
1, test method
1.1 grouping
The complete female C57BL/6J mouse 50,18.0~20.5g of weight for taking quarantine qualified, according to weight by random district's groups point
Group method is divided into 5 groups, i.e. Normal group, model control group, the four high, medium and low dosage groups of taste particle, every group of 10 animals.Grouping
Random number, group are corresponding with test number to be shown in Table 20.
20 random number of table, group table corresponding with test number
1.2 dose designs and foundation
Dose design：(1) test sample group：According to the Ministry of Public Health《Health food is examined and assessment technique specification》(version in 2003)
The middle function of physical fatigue alleviation method of inspection, " experiment sets three dosage groups and negative control group, and 10 times with human body recommended amounts are
One of dosage group separately sets two dosage groups ", 5,10,20 times of tested material day for human beings recommended amounts are pressed in this experiment, if four tastes
The basic, normal, high dosage of particle is followed successively by 1.34g/kg, 2.67g/kg and 5.34g/kg, is specifically shown in Table 21.
(2) Normal group：Give isometric purified water.
(3) model control group：Give isometric purified water.
1.3 medication
(1) administration route：Select clinical application approach --- gastric infusion.
(3) administered volume：Administered volume selects 10ml/kg.
(4) administration frequency and period：1 time a day, continuous 28d.Dosage regimen is shown in Table 21.
21 4 monosodium glutamate particle anti-oxidation efficacy development test dosage regimen of table
1.4 modeling methods and Testing index
(1) weight inspection：Administration phase is weighed weekly 1 time, and calculates animal dosage according to changes of weight.
(2) modeling method：It is administered the 22nd day, for each group while continuing administration, in addition to Normal group, each group animal is equal
The cyclophosphamide modeling of 40mg/10ml/kg BW is injected intraperitoneally, one time a day, continuous modeling 2 days, the 5th day after final injection administration
It is administered the 28th day and carries out antibody-producting cell detection.
It is prepared by 1.5 complements
5 cavy femoral artery are taken into blood in advance, stand 30-60min, 2500rpm, 15min detach serum, by guinea pig serum
After mixing, with hematocrit SRBC with 5：1 (v/v) ratio mixes, and 4 DEG C of refrigerators place 45min, or concussion, 2500rpm, 15min points
From serum, packing, -80 DEG C of refrigerators preserve.Used time is with complete medium 1：10 (v/v) dilution proportions.
1.6 immune animals：Be administered the 23rd day, hematocrit SRBC be made with physiological saline 2% (v/v) cell suspension (about 1 ×
108A SRBC), every mouse peritoneal injects 0.2ml.
It is prepared by 1.7 splenocyte suspensions：The mouse cervical dislocation of (administration the 28th day) is put to death after SRBC is immunized 5 days, sterile
Spleen is taken, and one piece of gauze is placed above in spleen, gently spleen is ground with large syringe inner core, individual cells suspension is made,
200 mesh screens filter, and 1000rpm/min, 10min go supernatant, Hank ' liquid to wash 2 times, are prepared with complete medium RPMI 1640
At 5 × 106The splenocyte suspension of a cell/mL.
The measurement of 1.8 plaques
1. prepared by bottom culture medium
It weighs about 0.5g agaroses to be added in 100mL sterile salines, dissolve by heating, when temperature is in 50 DEG C or so,
It is added in six well culture plates with the amount in the holes 1ml/, it is spare after agar solidification.
2. prepared by top layer culture medium
It weighs about 0.5g agaroses to be added in 100mL Hank ' s liquid (PH7.2-7.4), dissolve by heating, with 0.5mL/ test tubes
Amount add in the test tube of 48 DEG C of constant temperature.
3. bed board
Draw 50 μ l 20%SRBC (normal saline, v/v), 200 μ l splenocyte suspensions (5 × 106A/ml) successively
It is added in the test tube containing 0.5mL top layer culture mediums, top layer mixed liquor, each sample are poured into six orifice plates and paved to rapid mixing
Originally two parallel holes are done.
4. Plaque assay
The culture plate prepared is put into 37 DEG C, 5%CO2It is incubated 1h in incubator, 500 μ l are then added per hole with complete
The diluted complement of full culture medium (v/v, 1：10), continue to be incubated 2h, count hemolysis plaque number.
1.9 data statistics processing
Antibody-producting cell checks that data are measurement data, calculates average, standard deviation using Excel softwares, judges number
Whether according to being in normal distribution, normal distribution then uses F in excel to examine progress homogeneity test of variance, then selects t to examine and carry out
Statistics；If being in Non-Gaussian Distribution, non-parametric test is carried out.
1.10 result judgement
With plaque number/106Splenocyte indicates that the plaque number of test sample group is significantly higher than the plaque number of control group, can
Judge this experimental result positive.
2, result and analysis
22 4 monosodium glutamate particle strengthen immunity functional evaluation of table-antibody-producting cell detection test result
Note：1. model control group is compared with Normal group▲▲▲p<0.001 2. each administration group and model control group ratio
Compared with * * * p<0.001
Table 22 shows that compared with Normal group, 1. model control group hemolysis plaque number pole is substantially less than Normal group
(P<0.001), illustrate modeling success.2. compared with model is according to group, four monosodium glutamate particle high dose groups (5.34g crude drugs/kg), middle dose
Amount group (2.67g crude drugs/kg) and low dose group (1.34g crude drugs/kg) can pole significantly improve mouse hemolysis plaque number (P<
0.001).3. according to result judgement standard, " the plaque number of test sample group is significantly higher than the plaque number of control group, can determine that this
Experimental result is positive ", therefore judge that four monosodium glutamate particles have the function of strengthen immunity function.
Brief summary：Four monosodium glutamate particles in 2.67-5.34g crude drugs/kg dosage ranges there is enhancing to exempt from function.
Claims (7)
1. a kind of drug or health-care food composition for raising negative and positive, QI invigorating and blood, it is characterised in that：It is matched by following weight
The preparation that the raw material of ratio is prepared：
1 part of American Ginseng, 5 parts of matrimony vine, 5 parts of Radix Salviae Miltiorrhizae, 5 parts of Herba Epimedii.
2. composition according to claim 1, it is characterised in that：It is by American Ginseng, matrimony vine, Radix Salviae Miltiorrhizae, Herba Epimedii original
Crude drug powder, water or extractive with organic solvent are active constituent, and pharmaceutically acceptable auxiliary material is added or complementary ingredient is prepared into
Pharmaceutically common preparation.
3. composition according to claim 2, it is characterised in that：The preparation is tablet, granule, capsule, ball
Agent, oral solution, vina.
4. a kind of method preparing the composition described in claim 1-3 any one, it includes the following steps：
A, the raw material of each weight proportion is weighed；
B, extraction is added water to cook, is filtered, filtrate concentration is added pharmaceutically acceptable auxiliary material or complementary ingredient is prepared into pharmacy
Upper common preparation.
5. use of the composition in preparing the drug or health food of alleviating physical fatigue described in claim 1-3 any one
On the way.
6. purposes of the composition described in claim 1-3 any one in preparing oxidation resistant drug or health food.
7. use of the composition in the drug or health food for preparing strengthen immunity described in claim 1-3 any one
On the way.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510048005.6A CN104547270B (en) | 2015-01-29 | 2015-01-29 | It is a kind of to raise negative and positive, the drug of QI invigorating and blood or health-care food composition and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510048005.6A CN104547270B (en) | 2015-01-29 | 2015-01-29 | It is a kind of to raise negative and positive, the drug of QI invigorating and blood or health-care food composition and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104547270A CN104547270A (en) | 2015-04-29 |
| CN104547270B true CN104547270B (en) | 2018-10-19 |
Family
ID=53065041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510048005.6A Active CN104547270B (en) | 2015-01-29 | 2015-01-29 | It is a kind of to raise negative and positive, the drug of QI invigorating and blood or health-care food composition and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104547270B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1548143A (en) * | 2003-05-25 | 2004-11-24 | 杭州胡庆余堂药业有限公司 | Antifatigue Chinese medicine composition and its prepn process |
| CN1739626A (en) * | 2005-09-13 | 2006-03-01 | 孙景茂 | Tea extract dripping pill |
| CN102370170B (en) * | 2011-08-18 | 2013-03-27 | 高益槐 | Health-care food for relieving physical fatigue and preparation method thereof |
| CN103893386A (en) * | 2014-03-25 | 2014-07-02 | 胡方 | Health product for improving immunity and preparation method thereof |
-
2015
- 2015-01-29 CN CN201510048005.6A patent/CN104547270B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1548143A (en) * | 2003-05-25 | 2004-11-24 | 杭州胡庆余堂药业有限公司 | Antifatigue Chinese medicine composition and its prepn process |
| CN1739626A (en) * | 2005-09-13 | 2006-03-01 | 孙景茂 | Tea extract dripping pill |
| CN102370170B (en) * | 2011-08-18 | 2013-03-27 | 高益槐 | Health-care food for relieving physical fatigue and preparation method thereof |
| CN103893386A (en) * | 2014-03-25 | 2014-07-02 | 胡方 | Health product for improving immunity and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104547270A (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104383447B (en) | A kind of Traditional Chinese medicine composition and preparation method and application | |
| CN101269179A (en) | Traditional Chinese medicine preparation for treating senile dementia and preparation method thereof | |
| CN101732566B (en) | Traditional Chinese medicine compound preparation for tonifying liver and kidney and strengthening bones and muscles | |
| CN102266428B (en) | Anti-ageing Chinese medicinal composition and preparation method and application thereof | |
| CN103735621B (en) | A kind of Chinese medicine composition with blood fat reducing and enhancing immunity effect | |
| CN103108639A (en) | Composition of active ingredient of traditional chinese medicine and use thereof | |
| CN104547270B (en) | It is a kind of to raise negative and positive, the drug of QI invigorating and blood or health-care food composition and its preparation method and application | |
| CN104524292A (en) | Application of traditional Chinese medicine preparation in preparation of medicament for treating obesity | |
| CN102652774B (en) | Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method | |
| CN106880784A (en) | It is a kind of with fatigue-relieving, the Chinese medicine composition of anti-aging and its application | |
| CN106727898A (en) | A kind of pharmaceutical composition for preventing and treating Alzheimer disease and preparation method thereof | |
| CN100372557C (en) | Oral liquid capable of raising human body anoxia tolerance and its preparation method | |
| CN102406172B (en) | Health-care food for enhancing immunity and preparation method thereof | |
| CN104887766A (en) | Traditional Chinese medicine compound capsules for treating atherosclerosis and preparation method thereof | |
| CN105288501A (en) | Traditional Chinese medicine composition containing folium artemisiae argyi and treating obesity | |
| CN104189038A (en) | Traditional Chinese medicine preparation for regulating female physical health and immunity | |
| CN104547738A (en) | Traditional Chinese medicine preparation for treating obesity and preparation method of traditional Chinese medicine preparation | |
| CN101317900A (en) | Chinese medicinal composition for preventing and controlling alcoholic liver damnification and preparation method thereof | |
| CN108578573A (en) | A kind of composition and its preparation method and application with kidney-replenishing, strengthen immunity and alleviation fatigue effect | |
| CN116870063B (en) | Traditional Chinese medicine composition with blood circulation activating and nerve soothing functions and preparation method thereof | |
| CN115919968B (en) | Traditional Chinese medicine composition for treating ischemic stroke and preparation method thereof | |
| CN104758719B (en) | A kind of Chinese medicine composition, granule and preparation method for treating leukopenia | |
| CN110478450B (en) | Pharmaceutical composition for treating Alzheimer disease and application thereof | |
| CN109222094A (en) | A kind of antifatigue complex capsule and preparation method thereof | |
| CN109170914A (en) | A kind of anti-fatigue health-caring composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 646607 Luzhou city of Sichuan province Wangjiang town ponds Longmatan district road two No. six, No. eight Applicant after: Sichuan green leaf pharmaceutical Limited by Share Ltd Address before: 646607 Luzhou city of Sichuan province Wangjiang town ponds Longmatan district road two No. six, No. eight Applicant before: SICHUAN LVYE BAO GUANG PHARMACEUTICAL INDUSTRY CO., LTD. |
|
| COR | Change of bibliographic data | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |